STAT3 and leukocyte adhesion deficiency: Moreover, using the TCGA LAD datasets, Kaplan–Meier analysis showed that LAD patients bearing high VAL expression in their lung tumors displayed a significantly shorter median survival time of 36.9 months and lower 5-year survival rate of 27.56%, compared with the 60.0-month median survival and 49.34%-rate 5-year survival for those with low VAL expression; in parallel, high VAL levels negatively correlates with short recurrence-free survival (Fig. 1o, p), suggesting that aberrant VAL expression induced by AKT/STAT3 activation might play important roles during LAD development and progression.